Market Overview

Afternoon Market Gainers

Share:
Related BLUE
These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold
Bluebird Bio Initiated Hold At Cantor Fitzgerald, Decides To Await Additional Data
Related NKTR
Brean Weighs In On Nektar ONZEALD Deal
Nektar Therapeutics Presents Pre-Clinical Data Combining NKTR 214 With Checkpoint Blockade

Bluebird Bio (NASDAQ: BLUE) traded up 49.55 percent to $25.41. Wednesday's IPO for the company was initially priced at $17.

Nektar Therapeutics (NASDAQ: NKTR) rose 9.99 percent to $10.79 after announcing positive top-line results from a human abuse liability (HAL) study for NKTR-181.

Gevo (NASDAQ: GEVO) climbed 9.23 percent to $2.26 after yesterday's announcement that it had resumed commercial production of Isobutanol.

Keryx BioPharma (NASDAQ: KERX) shot up 6.50 percent to $8.16 after analysts at JP Morgan initiated coverage on the stock with an Overweight rating.

MannKind (NASDAQ: MNKD) regained 6.48 percent to $7.03 after yesterday's double-digit drop.

Posted-In: News Movers

 

Related Articles (GEVO + BLUE)

View Comments and Join the Discussion!